Rivaroxaban (Xarelto, BAY59-7939) + Warfarin
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-valvular Atrial Fibrillation (NVAF)
Conditions
Non-valvular Atrial Fibrillation (NVAF)
Trial Timeline
Oct 6, 2021 → Oct 24, 2022
NCT ID
NCT05022758About Rivaroxaban (Xarelto, BAY59-7939) + Warfarin
Rivaroxaban (Xarelto, BAY59-7939) + Warfarin is a pre-clinical stage product being developed by Bayer for Non-valvular Atrial Fibrillation (NVAF). The current trial status is completed. This product is registered under clinical trial identifier NCT05022758. Target conditions include Non-valvular Atrial Fibrillation (NVAF).
What happened to similar drugs?
2 of 3 similar drugs in Non-valvular Atrial Fibrillation (NVAF) were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05022758 | Pre-clinical | Completed |
| NCT04509193 | Pre-clinical | Completed |
Competing Products
17 competing products in Non-valvular Atrial Fibrillation (NVAF)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edoxaban | Daiichi Sankyo | Pre-clinical | 26 |
| DU-176b 15mg + DU-176b 30mg + DU-176b 60mg | Daiichi Sankyo | Phase 3 | 40 |
| Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin | Daiichi Sankyo | Approved | 39 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 26 |
| AZD0837 + Aspirin | AstraZeneca | Phase 2 | 35 |
| Apixaban + Warfarin | Pfizer | Pre-clinical | 26 |
| Warfarin + Apixaban | Pfizer | Pre-clinical | 26 |
| Apixaban | Bristol Myers Squibb | Approved | 43 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 18 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban(Xarelto,BAY 59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto,Bay 59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY-597939) + VKAs | Bayer | Pre-clinical | 23 |
| Non-VKA Oral Anticoagulants (NOAC) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto_ BAY59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan) | Bayer | Pre-clinical | 15 |